Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH. de Zeeuw D, et al. Among authors: kohan d. J Am Soc Nephrol. 2014 May;25(5):1083-93. doi: 10.1681/ASN.2013080830. Epub 2014 Apr 10. J Am Soc Nephrol. 2014. PMID: 24722445 Free PMC article. Clinical Trial.
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
Kohan DE, Lambers Heerspink HJ, Coll B, Andress D, Brennan JJ, Kitzman DW, Correa-Rotter R, Makino H, Perkovic V, Hou FF, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D. Kohan DE, et al. Among authors: de zeeuw d. Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1568-74. doi: 10.2215/CJN.00570115. Epub 2015 Jul 7. Clin J Am Soc Nephrol. 2015. PMID: 26153128 Free PMC article. Clinical Trial.
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
Schievink B, de Zeeuw D, Smink PA, Andress D, Brennan JJ, Coll B, Correa-Rotter R, Hou FF, Kohan D, Kitzman DW, Makino H, Parving HH, Perkovic V, Remuzzi G, Tobe S, Toto R, Hoekman J, Lambers Heerspink HJ. Schievink B, et al. Among authors: de zeeuw d, kohan d. Eur J Prev Cardiol. 2016 May;23(7):758-68. doi: 10.1177/2047487315598709. Epub 2015 Jul 30. Eur J Prev Cardiol. 2016. PMID: 26229089 Free PMC article. Clinical Trial.
Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Heerspink HJ, Makino H, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Davis JW, Idler K, Kohan DE, Liu M, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D. Heerspink HJ, et al. Among authors: kohan de, de zeeuw d. Diabetes Obes Metab. 2017 Apr;19(4):545-552. doi: 10.1111/dom.12851. Epub 2017 Jan 27. Diabetes Obes Metab. 2017. PMID: 27981738 Clinical Trial.
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
Pena MJ, de Zeeuw D, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Kohan DE, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, Sharma S, Corringham T, Sharma K, Heerspink HJL. Pena MJ, et al. Among authors: kohan de, de zeeuw d. Diabetes Obes Metab. 2017 May;19(5):749-753. doi: 10.1111/dom.12864. Epub 2017 Feb 22. Diabetes Obes Metab. 2017. PMID: 28019071 Clinical Trial.
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
Webb DJ, Coll B, Heerspink HJL, Andress D, Pritchett Y, Brennan JJ, Houser M, Correa-Rotter R, Kohan D, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Busch R, Pergola P, Parving HH, de Zeeuw D. Webb DJ, et al. Among authors: de zeeuw d, kohan d. Drugs R D. 2017 Sep;17(3):441-448. doi: 10.1007/s40268-017-0201-0. Drugs R D. 2017. PMID: 28831752 Free PMC article. Clinical Trial.
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D. Heerspink HJL, et al. Among authors: de zeeuw d, kohan d. Diabetes Obes Metab. 2018 Jun;20(6):1369-1376. doi: 10.1111/dom.13245. Epub 2018 Mar 9. Diabetes Obes Metab. 2018. PMID: 29405626 Free PMC article.
Baseline characteristics and enrichment results from the SONAR trial.
Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D. Heerspink HJL, et al. Among authors: de zeeuw d, kohan d. Diabetes Obes Metab. 2018 Aug;20(8):1829-1835. doi: 10.1111/dom.13315. Epub 2018 May 1. Diabetes Obes Metab. 2018. PMID: 29604160 Free PMC article. Clinical Trial.
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Among authors: de zeeuw d, kohan d. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
219 results